H.C. Wainwright maintains Buy rating on Neumora stock ahead of obesity drug data

Investing.com - H.C. Wainwright has reiterated its Buy rating and $18.00 price target on Neumora Therapeutics (NASDAQ:NMRA), representing significant upside from the current price of $1.71. According to InvestingPro data, analyst targets range from $2 to $18, with the stock showing high volatility (Beta: 2.95).

The meeting, scheduled for October 27, will highlight progress on NMRA-215, Neumora’s NLRP3 inhibitor being developed for obesity treatment.

During the event, Neumora plans to present data from the diet-induced obesity (DIO) mouse model, which will reveal the clinical potential of this early-stage asset.

H.C. Wainwright noted that NMRA-215 could potentially enter a multi-billion-dollar market, with three other NLRP3 inhibitors currently in Phase 1/2 clinical trials for obesity treatment and multiple candidates at the preclinical stage.

The firm maintained its positive outlook on Neumora, reaffirming both its Buy recommendation and $18 price target for the stock.

In other recent news, Neumora Therapeutics reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of -$0.33, compared to the forecasted -$0.45. This represents a positive surprise of 26.67%. Despite this earnings beat, Neumora’s stock performance did not reflect this achievement. Stifel has maintained its Hold rating and a price target of $2.00 on Neumora Therapeutics. This decision follows the company’s recent earnings report and the failure of navacaprant in the KOASTAL-1 major depressive disorder trial. In response, Neumora has adopted more rigorous approaches for its upcoming KOASTAL-2 and KOASTAL-3 studies, with results expected in the first and second quarters of 2026. The company’s strong cash position and ongoing clinical trials present an optimistic outlook, though broader market conditions may continue to impact investor sentiment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.